SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today that the Centers for Medicare and ...
SAN FRANCISCO, December 09, 2025--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate ...
The ArteraAI Prostate Test uses AI to analyze biopsy images, predicting hormone therapy benefits for prostate cancer patients. Approved in the US and UK, the test aids early diagnostic decisions, ...
CORRECTED January 18, 2024 // Editor's note: An earlier version of this story erroneously stated that Medicare has started covering use of the AI-based cancer test. Neither the company nor CMS ...
Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted Breakthrough Device Designation by the FDA for its ArteraAI Prostate, an AI-enabled tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback